

PARIS 2022 **ESMO** congress
PARIS FRANCE
9-13 SEPTEMBER 2022



Les GCO à l'ESMO 2022

ARCAGY-GINECO – Cancers gynécologiques

Maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): final overall survival (OS) results from the Phase III PAOLA-1/ENGOT-ov25 trial.

Isabelle Ray-Coquard

[Proffered Paper session](#)

ATALANTE/ENGOT ov29 Phase III trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with ovarian cancer (OC) platinum-sensitive relapse (PSR)

Jean-Emmanuel Kurtz

[Proffered Paper session](#)

Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: the case-control vivrovaire rare tumors study

Florence Joly

[Poster](#)

Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial.

Fabrice Lécuru

[Poster](#)

NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP-bevacizumab (bev) followed by nira-bev in patients with FIGO Stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery

Gilles Freyer

[Poster](#)

FFCD – Cancers digestifs

PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

David Tougeron

[Mini oral session](#)

LBA46 - Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

Thomas Walter

Mini oral session

Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

Julien Taieb

Proffered Paper session

LBA28 - Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial

Come Lepage

Mini oral session

Management of localized anal cancer and prognostic factors in the elderly: results of the French multicenter cohort FFCD –ANABASE

Claire Gouriou

Poster

A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial

Claire Gallois

Poster

GERCOR

Impact of age on treatment strategies in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): A prespecified subgroup analysis of the GERCOR-PRODIGE STRATEGIC-1 phase III study

Elisabeth Carola

e-poster

Multi-line therapy trial in unresectable wild-type RAS/BRAF metastatic colorectal cancer (mCRC): results from the randomized phase III STRATEGIC-1 GERCOR-PRODIGE phase III study

IFCT – Cancers thoraciques

Nivolumab (Nivo) plus Ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced Non-Small-Cell-Lung Cancer (aNSCLC): results of the randomized IFCT-1701 phase 3 trial

Gérard Zalcman

Proffered paper session

Capmatinib for METex14 non-small cell lung cancer patients: results of the real-world study IFCT-2104 CapmATU

Marion Ferreira

Poster

Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network

Jose Carlos Benitez (Gustave Roussy, Villejuif)

Poster